← back to search

Lene Dreyer

Parker Institute for Cancer Immunotherapy · US
Area of research
Rheumatology · Immunology
Research interest
Research focused on Rheumatoid arthritis and Abatacept, with related work in Systemic lupus, Lymphoma, Systemic lupus erythematosus. Notable publications include 'Cancer risk in systemic lupus: An updated international multi-centre cohort study', 'Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers', and 'Lymphoma risk in systemic lupus: effects of disease activity versus treatment'.
h-index
citations
1,278
works
14
NIH funding
primary concept
email

Recent publications

Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)
Annals of the Rheumatic Diseases 2023cited by 22position: middledoi
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
Annals of the Rheumatic Diseases 2022cited by 142position: middledoi
Biological Disease-Modifying Antirheumatic Drugs and Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis: A Danish Cohort Study
The American Journal of Medicine 2022cited by 15position: middledoi
The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries
Lara D. Veeken 2021cited by 15position: middledoi
OP0231 COMPARATIVE EFFECTIVENESS OF JAK-INHIBITORS, TNF-INHIBITORS, ABATACEPT AND IL-6 INHIBITORS IN AN INTERNATIONAL COLLABORATION OF REGISTERS OF RHEUMATOID ARTHRITIS PATIENTS (THE “JAK-POT” STUDY)
Annals of the Rheumatic Diseases 2020cited by 31position: middledoi
Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden
Annals of the Rheumatic Diseases 2019cited by 66position: middledoi
Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data
Lara D. Veeken 2018cited by 18position: middledoi
Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project
Annals of the Rheumatic Diseases 2017cited by 93position: middledoi
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
Annals of the Rheumatic Diseases 2016cited by 186position: middledoi
Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers
Annals of the Rheumatic Diseases 2016cited by 131position: middledoi
Cardiac Abnormalities in Adult Patients With Polymyositis or Dermatomyositis as Assessed by Noninvasive Modalities
Arthritis Care & Research 2015cited by 66position: middledoi
Cancer risk in systemic lupus: An updated international multi-centre cohort study
Journal of Autoimmunity 2013cited by 300position: middledoi
Lymphoma risk in systemic lupus: effects of disease activity versus treatment
Annals of the Rheumatic Diseases 2013cited by 159position: middledoi
Non-Lymphoma Hematological Malignancies in Systemic Lupus Erythematosus
Oncology 2013cited by 34position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Johan Askling · Karolinska University Hospital5 papers (2016–2021)Merete Lund Hetland · University of Copenhagen5 papers (2016–2021)Kimme L Hyrich · University of Manchester4 papers (2016–2020)René Cordtz · Parker Institute for Cancer Immunotherapy3 papers (2017–2022)Florenzo Iannone · University of Padua3 papers (2016–2020)Anja Strangfeld · German Rheumatism Research Centre3 papers (2016–2020)Bente Glintborg · AbbVie (United States)3 papers (2016–2021)Søren Jacobsen · Dalhousie University2 papers (2013–2015)Louise Mercer · University of Manchester2 papers (2016–2017) · 2 papers (2016–2017)Axel Finckh · University of Geneva2 papers (2016–2020)Karin Hellgren · Karolinska Institutet2 papers (2016–2017)Jakub Závada · AbbVie (United States)2 papers (2016–2017)Elizabeth V. Arkema · Karolinska Institutet2 papers (2016–2019)Jacques Morel · Rolex SA (Switzerland)2 papers (2016–2017)L. Jacobsson · Amgen (United States)2 papers (2016–2021)A. Zink · Charité - Universitätsmedizin Berlin2 papers (2016–2017)Joachim Listing · Charité - Universitätsmedizin Berlin2 papers (2016–2017) · 2 papers (2016–2017) · 2 papers (2016–2017)